Federal Register / Vol. 73, No. 154 / Friday, August 8, 2008 / Notices 46299 

Dated: July 24, 2008. 

Penelope Slade Royall, 

RADM, USPHS, Deputy Assistant Secretary 

for Health, (Disease Prevention and Health 

Promotion). 

[FR Doc. E8–18299 Filed 8–7–08; 8:45 am] 

BILLING CODE 4150–32–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Preparedness, 

Detection, and Control of Infectious 

Diseases 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following committee 

meeting. 

Name: Clinical Laboratory Improvement 

Advisory Committee (CLIAC). 

Times and Dates: 8:30 a.m.–5 p.m., 

September 10, 2008; 8:30 a.m.–3 p.m., 

September 11, 2008. 

Place: Centers for Disease Control and 

Prevention, 1600 Clifton Road, NE., Tom 

Harkin Global Communications Center, 

Building 19, Room 232, Auditorium B, 

Atlanta, Georgia 30333. 

New Information—Online Registration 

Required: In order to expedite security 

clearance process at the CDC Roybal Campus 

located on Clifton Road, all CLIAC attendees 

are required to register in advance for the 

meeting at http://www.cdc.gov/cliac/ 

default.aspx by clicking the Register for a 

‘‘Meeting’’ link and completing all forms 

according to the instructions given. Please 

complete all the required fields and submit 

your registration as far in advance of the 

meeting date as possible. 

Note: The cut-off date for registration for 

domestic attendees is Thursday, September 

4, 2008; the cut-off date for international 

attendees to register is Monday, August 25, 

2008. 

Status: Open to the public, limited only by 

the space available. The meeting Room 

accommodates approximately 100 people. 

Purpose: This Committee is charged with 

providing scientific and technical advice and 

guidance to the Secretary of Health and 

Human Services, the Assistant Secretary for 

Health, and the Director, CDC, regarding the 

need for, and the nature of, revisions to the 

standards under which clinical laboratories 

are regulated; the impact on medical and 

laboratory practice of proposed revisions to 

the standards; and the modification of the 

standards to accommodate technological 

advances. 

Matters to Be Discussed: The agenda will 

include updates from the CDC, the Centers 

for Medicare & Medicaid Services, and the 

Food and Drug Administration; a report from 

the CLIAC Workgroup on Good Laboratory 

Practices for Genetic Testing, and discussion 

of the Workgroup’s proposals related to such; 

presentations and discussion related to 

laboratory quality control through risk 

management; and an introduction to the 

status of waived testing and discussion of the 

potential for waiver of automated hematology 

devices. Agenda items are subject to change 

as priorities dictate. 

Providing Oral or Written Comments: It is 

the policy of CLIAC to accept written public 

comments and provide a brief period for oral 

public comments whenever possible. 

Oral Comments: In general, each 

individual or group requesting to make an 

oral presentation will be limited to a total 

time of five minutes (unless otherwise 

indicated). Speakers must also submit their 

comments in writing for inclusion in the 

meeting’s Summary Report. To assure 

adequate time is scheduled for public 

comments, individuals or groups planning to 

make an oral presentation should, when 

possible, notify the contact person below at 

least one week prior to the meeting date. 

Written Comments: For individuals or 

groups unable to attend the meeting, CLIAC 

accepts written comments until the date of 

the meeting (unless otherwise stated). 

However, the comments should be received 

at least one week prior to the meeting date 

so that the comments may be made available 

to the Committee for their consideration and 

public distribution. Written comments, one 

hard copy with original signature, should be 

provided to the contact person below. 

Written comments will be included in the 

meeting’s Summary Report. 

Contact Person for Additional Information: 

Nancy Anderson, Chief, Laboratory Practice 

Standards Branch, Division of Laboratory 

Systems, National Center for Preparedness, 

Detection, and Control of Infectious Diseases, 

Coordinating Center for Infectious Diseases, 

CDC, 1600 Clifton Road, NE., Mailstop F–11, 

Atlanta, Georgia 30333; telephone (404) 498–

2741; fax (404) 498–2219; or via e-mail at 

Nancy.Anderson@cdc.hhs.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register Notices 

pertaining to announcements of meetings and 

other committee management activities, for 

CDC and the Agency for Toxic Substances 

and Disease Registry. 

Dated: July 28, 2008. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. E8–18285 Filed 8–7–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Health Statistics 

(NCHS), Classifications and Public 

Health Data Standards Staff; 

Modifications to the International 

Classification of Diseases, Ninth 

Revision, Clinical Modification (ICD–9–

CM), Supplementary Classification of 

External Causes of Injury and 

Poisoning 

ACTION: Notice. 

National Center for Health Statistics 

(NCHS), Classifications and Public 

Health Data Standards Staff, announces 

the following modifications to the 

International Classification of Diseases, 

Ninth Revision, Clinical Modification 

(ICD–9–CM), Supplementary 

Classification of External Causes of 

Injury and Poisoning. These codes will 

become effective October 1, 2008. 

External Cause Tabular 

New code E927.0 Overexertion from 

sudden strenuous movement. Sudden 

trauma from strenuous movement 

New code E927.1 Overexertion from 

prolonged static position 

New code E927.2 Excessive physical 

exertion from prolonged activity 

New code E927.3 Cumulative trauma 

from repetitive motion 

New code E927.4 Cumulative trauma 

from repetitive impact 

New code E927.8 Other overexertion 

and strenuous and repetitive 

movements or loads 

New code E927.9 Unspecified 

overexertion and strenuous and 

repetitive movements or loads 

CONTACT PERSON FOR ADDITIONAL

INFORMATION: Donna Pickett, Medical 

Systems Specialist, Classifications and 

Public Health Data Standards Staff, 

NCHS, 3311 Toledo Road, Room 2402, 

Hyattsville, Maryland 20782, e-mail 

dfp4@cdc.gov, telephone 301–458–4434. 

The complete diagnosis addenda may be 

accessed on the NCHS Web site using 

the URL: http://www.cdc.gov/nchs/ 

datawh/ftpserv/ftpicd9/ 

ftpicd9.htm#addenda. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to modifications to 

the ICD–9–CM, for both CDC and the 


pwalker on PROD1PC71 with NOTICES
46300 Federal Register / Vol. 73, No. 154 / Friday, August 8, 2008 / Notices 

Agency for Toxic Substances and 

Disease Registry. 

Daniel Riedford, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E8–18284 Filed 8–7–08; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 73 FR 35140, dated 

June 20, 2008) is amended to reflect the 

reorganization of the Office of the 

Director, Centers for Disease Control 

and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: Delete in their entirety the titles 

and functional statements for the Office 

of Strategy and Innovation (CAM) and 

the Office of Chief of Public Health 

Practice (CAR) and insert the following: 

Office of Strategy and Innovation 

(CAM). The Office of Strategy and 

Innovation (OSI) serves as the focal 

point for accelerating the health impact 

of CDC’s work within and beyond CDC’s 

programs. In carrying out its mission, 

OSI: (1) Leads CDC’s efforts to develop, 

monitor, evaluate, and advance agency 

strategic direction, planning, and 

priorities; (2) fosters strategic excellence 

and innovation across the agency; (3) 

provides superior decision support to 

CDC’s executive leadership; (4) leads 

the development of health in all 

policies; (5) promotes the health, safety, 

and quality of life of women; and (6) 

improves the health of the public 

through law. 

Office of the Director (CAM1). (1) 

Develops, monitors, and advances 

CDC’s strategic direction, planning, and 

priorities; (2) provides leadership and 

vision for formulating and evaluating 

policy; (3) fosters strategic excellence 

and innovation across the agency; (4) 

applies knowledge management tools 

and decision support systems in 

allocation of resources and improves 

agency decision-making; (5) 

communicates key messages to CDC 

employees and partners about CDC’s 

strategic direction, planning, and 

priorities; and (6) works directly with 

the strategy and innovation officers 

within the coordinating centers to 

develop, monitor, and advance CDC 

strategic direction and priorities and 

institutionalize organizational change, 

improvement, and accountability. 

Office of Women’s Health (CAM12). 

The Office of Women’s Health (OWH) 

aims to promote and improve the 

health, safety, and quality of life of 

women. As a leader for women’s health 

issues at CDC, the Office of Women’s 

Health: (1) Advises the CDC Director on 

matters relating to women’s health 

research, programs, and strategies; (2) 

promotes the health and well-being of 

women; (3) communicates health 

information, research findings, and 

prevention strategies to a diverse group 

of providers, consumers, and 

organizations; (4) advances sound 

scientific knowledge for public health 

action, promotes the role of prevention, 

and works to improve the 

understanding of women’s health 

priorities; (5) fosters partnerships and 

collaborations within CDC and with 

other public and private organizations, 

agencies, institutions, and others to 

improve the health and safety of 

women; (6) publishes newsletters and 

other documents that highlight 

prevention programs, research findings, 

publications, health campaigns, health 

promotion strategies, and other 

information available at CDC; (7) leads 

CDC Women’s Health Committee by 

facilitating and coordinating agencywide efforts and enhancing channels for 

communication and cooperation; (8) 

supports the development of future 

women’s health and public health 

professionals through various training 

and student positions within the office; 

(9) prepares agency reports, briefing 

documents, and other materials 

addressing women’s health issues; (10) 

stimulates and supports prevention 

research, programs, and other activities 

through funding; (11) represents the 

agencies at meetings, committees, 

workgroups, conferences, and briefings; 

(12) serves as liaison for women’s health 

between CDC and other agencies and 

organizations; (13) develops 

opportunities for, promotes, and 

supports the agency as a resource for 

women’s health issues; and (14) 

provides assistance to state and local 

programs on women’s health issues. 

Public Health Law Program (CAM13). 

The mission of the Public Health Law 

Program is to improve the health of the 

public through law. The program: (1) 

Provides technical assistance to CDC 

centers and to extramural partners in 

developing their legal preparedness to 

address the full spectrum of health 

protection goals; (2) collaborates with 

CDC and extramural partners in 

developing tools for use in assessing 

and improving the public health legal 

preparedness of the health system; (3) 

strengthens the competencies of 

practitioners in public health, 

emergency management, law, and other 

sectors to apply law to improve public 

health; (4) supports and conducts 

applied research in public health law 

and translates findings into practice; (5) 

provides consultation and analysis in 

public health law to CDC programs and 

extramural constituents; (6) establishes 

partnerships among CDC and other 

organizations active in public health 

law and assists in strengthening their 

public health law capacity and 

expertise; and (7) develops and 

disseminates authoritative information 

on public health law and public health 

law best practices to practitioners and 

policy makers. 

Office of Chief of Public Health 

Practice (CAR). The Office of Chief of 

Public Health Practice (OCPHP) serves 

as the advocate, guardian, promoter, and 

conscience of public health practice 

throughout CDC and in the larger public 

health community; ensures coordination 

and synergy of CDC’s scientific and 

practice activities; and promotes and 

protects the public’s health through 

science-based, practice-relevant 

standards, policies, and legal tools. To 

carry out its mission, OCPHP: (1) 

Establishes robust partnerships among 

CDC programs, public health 

practitioners and key sectors, including 

elected officials, the legal community, 

and law enforcement and emergency 

response organizations; (2) establishes a 

functional area focused specifically on 

standards and improvement in practice 

among state and local public health 

systems; (3) advances the development 

and implementation of a national 

agency accreditation system; (4) relates 

relevant research and policy analysis to 

public health practice; (5) monitors and 

anticipates public health practice trends 

and issues; and (6) coordinates and 

addresses cross-cutting issues related to 

public health practice within CDC; and 

(7) develops, monitors and advances 

agency-wide goals for improving health 

equity, fostering strategic excellence and 

innovation across CDC, and 

organizational development and the 

transition process. 


pwalker on PROD1PC71 with NOTICES